fimasartan and Neointima

The beneficial effects of angiotensin II type 1 receptor blockers (ARBs) on atherosclerosis have been demonstrated in numerous studies. We investigated the effects of fimasartan on reducing neointimal formation and systemic inflammation after carotid artery (CA) injury in Apolipoprotein E knockout (ApoE KO) mice.. ApoE KO mice were randomly allocated to Group I (without CA injury), Group II (without CA injury + Fimasartan), Group III (CA injury), and Group IV (CA injury + Fimasartan). Fimasartan was orally administered everyday starting 3 days before iatrogenic left CA injury.. At 28 days, neointimal hyperplasia and the inflammatory cytokines including TNFα, IL-6, ICAM, and MMP-9 in the peripheral blood were significantly reduced in Groups II and IV compared to Groups I and III, respectively. All fimasartan-administered groups revealed significant increases of CD4. This study suggests fimasartan could be an efficient strategy for reduction of atherosclerotic progression, with a decrease in immune response and systemic inflammation.

Topics: Angiotensin Receptor Antagonists; Animals; Apolipoproteins E; Biphenyl Compounds; Carotid Artery Injuries; Inflammation; Interleukin-6; Male; Matrix Metalloproteinase 9; Mice; Mice, Knockout; Neointima; Pyrimidines; T-Lymphocytes, Regulatory; Tetrazoles; Tumor Necrosis Factor-alpha